Sustained Efficacy and Safety of Vardenafil for Treatment of Erectile Dysfunction: A Randomized, Double-Blind, Placebo-Controlled Study

Valiquette, Luc; Young, Jay M.; Moncada, Ignacio; Porst, Hartmut; V├ęzina, Jean-Guy; Stancil, Britt-Nicole; Edmunds, Katharine; Montorsi, Francesco
October 2005
Mayo Clinic Proceedings;Oct2005, Vol. 80 Issue 10, p1291
Academic Journal
OBJECTIVE: To evaluate the reliability, efficacy, and safety of vardenafil, 10 mg, for patients with erectile dysfunction. PATIENTS AND METHODS: Vardenafil-naive patients completed a 4-week treatment-free run-in phase and a 1-week single-dose vardenafil (10 rag) open-label challenge phase. Responders to vardenafil in the challenge phase were randomized to 12 weeks of double-blind, fixed-dose treatment with vardenafil at 10 mg or placebo. Diary responses to Sexual Encounter Profile (SEP) questions about erections and attempts at sexual activity were collected after 4, 8, and 12 weeks of randomized treatment. Adverse events were monitored throughout the study. RESULTS: During the open-label challenge phase, the proportions of patients with a first-time success for penetration (SEP2) and maintenance of erection (SEP3) were 87% and 74%, respectively. Of 600 patients challenged with a single dose of vardenafil at 10 mg, 260 were randomized to vardenafil and 263 to placebo. During the double-blind phase, the reliability of penetration and maintenance rates for patients successful during the challenge phase were significantly greater with vardenafil compared with placebo (83.4% vs 55.8% [SEP2] and 76.6% vs 42.1% [SEP3], respectively). At week 12, patients in the vardenafil group had a consistently higher least squares mean (SE) on the erectile function domain score of the International Index of Erectile Function domain score of the International Index of Erectile Function than patients in the placebo group (23.5 !0.4] vs 15.8 respectively [last observation carried forward]) and a greater proportion of positive responses to the Global Assessment Question (80.8% vs 32.3%, respectively [last observation carried forward]) at each assessment (P<.O01). Vardenafil was generally well tolerated; most adverse events wore mild to moderate, with headache and flushing reported most frequently. CONCLUSION: During this 12-week study, vardenafil produced consistently higher reliability of penetration and maintenance of erection rates compared to placebo and was generally well tolerated in patients with erectile dysfunction.


Related Articles

  • Vivus drug ineffective in premature ejaculation.  // PharmaWatch: CNS;August 2003, Vol. 2 Issue 8, p26 

    Reports on the result of a clinical trial indicating the failure of an investigational compound VI-0162, a drug developed by U.S.-based Vivus Inc., to demonstrate an increase in the time to ejaculation. Result of previous studies suggesting that the drug was associated with an increased time to...

  • Clinical trial designs: is it possible to have a unified approach and common end points? Hedlund, H. // International Journal of Impotence Research;2002 Supplement 1, Vol. 14 Issue 1, p35 

    The accelerating development during the last 5 y of new compounds for the medical treatment of erectile dysfunction (ED) demands standardized high-quality protocols for evaluation of the therapeutic effect of these treatments. Outcome analyses have to rely on prospective, placebocontrolled...

  • Injection therapy salvages 25% of PDE-5 failures. Tennant, Scott // Urology Times;6/1/2008, Vol. 36 Issue 7, p6 

    The article discusses the study on the efficacy of intracavernosal injection (ICI) therapy for the treatment of erectile dysfunction. The clinical trial conducted at Weill-Cornell Medical Center and at the Memorial Sloan-Kettering Cancer Center in New York revealed that men who fail to respond...

  • VARDENAFIL IMPROVES ERECTILE FUNCTION REGARDLESS OF AGE.  // Worldwide Biotech;Jun2001, Vol. 13 Issue 6, p1 

    Provides information on Verdenafil, an investigational phosphodiesterase-5 inhibitor, devolved by the Bayer company to improve erectile function.

  • By fleeing death with Viagra, many may actually be pursuing it. Chase, Alston // Enterprise/Salt Lake City;06/01/98, Vol. 27 Issue 49, p17 

    Focuses on the high demand from people for the new potency drug, Viagra. Number of prescriptions filed by pharmacists for the drug daily; Hopes of eternal youth as the driving factor for the increased demand for the drug; Number of deaths reported by Viagra's manufacturer Pfizer Inc., resulting...

  • Competition for Viagra? Beyzarov, Elena Portyansky // Drug Topics;5/1/2000, Vol. 144 Issue 9, p30 

    Comments on the benefits of Uprima, an apomorphine drug for erectile dysfunction. Tests conducted for the drug; Effectivity and side effects; Chemical composition.

  • One man's drug is another man's metaphor. Dolliver, Mark // Adweek Eastern Edition;3/22/1999, Vol. 40 Issue 12, p22 

    Focuses on the free publicity given to the potency drug Viagra resulting from its references in several advertisements for unrelated brands. Overview on various advertising campaigns which attempts to relate its brands to the drug.

  • Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction. Porst, H // International Journal of Impotence Research;2000 Supplement 4, Vol. 12 Issue 5, pS91 

    Thirty percent of males afflicted with erectile dysfunction (ED) do not respond to oral drugs, another 15% reveal contraindications to currently available therapy, and a subset of patients actually prefer injection therapy due to its predictable short time-to-onset of erection and reliable...

  • Survey finds ED drug is used recreationally.  // Urology Times;Nov2003, Vol. 31 Issue 11, p56 

    Reports on the findings of a study regarding the use of Viagra as a recreational drug for men without signs of erectile disorders.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics